Maxim Group analyst Anthony Vendetti maintained a Buy rating on Sensus Healthcare Inc (NASDAQ: SRTS) today and set a price target of $10. The company’s shares closed yesterday at $6.50.
Vendetti noted:
“The company reported positive 3Q18 results, including slightly higher revenue and a narrower-than-expected GAAP EPS loss. Sensus shipped 18 total systems in the quarter, slightly below our estimate of 20, bringing its total installed base to 389 systems. We continue to expect FDA 510(k) clearance for Sculptura, the company’s intraoperative radiation therapy (IORT) system, by year-end, and commercialization in early 2019. The company also launched its SRT-100+ system in August 2018. We are introducing quarterly estimates for 2019.”
According to TipRanks.com, Vendetti is a 5-star analyst with an average return of 11.3% and a 56.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
Currently, the analyst consensus on Sensus Healthcare Inc is a Strong Buy with an average price target of $10.80, representing a 66.2% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $12 price target.
.
See today’s analyst top recommended stocks >>
Based on Sensus Healthcare Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $540.7K. In comparison, last year the company had a GAAP net loss of $965.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
